123 related articles for article (PubMed ID: 2597459)
1. Fall of cholesterol with time on dialysis: impact on atherogenicity.
Lapuz M; Avram MM; Lustig A; Goldwasser P; Antignani A; Fein PA; Mittman N
ASAIO Trans; 1989; 35(3):258-60. PubMed ID: 2597459
[TBL] [Abstract][Full Text] [Related]
2. The uremic dyslipidemia: a cross-sectional and longitudinal study.
Avram MM; Goldwasser P; Burrell DE; Antignani A; Fein PA; Mittman N
Am J Kidney Dis; 1992 Oct; 20(4):324-35. PubMed ID: 1415199
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal survey of apolipoproteins and atherogenic risk in hemodialysis and continuous ambulatory peritoneal dialysis patients.
Burrell D; Antignani A; Fein PA; Goldwasser P; Mittman N; Avram MM
ASAIO Trans; 1990; 36(3):M331-5. PubMed ID: 2123635
[TBL] [Abstract][Full Text] [Related]
4. The impact of CAPD treatment on lipid metabolism and cardiovascular risk.
Tan D; Fein PA; Antignani A; Mittman N; Avram MM
Adv Perit Dial; 1990; 6():233-7. PubMed ID: 1982815
[TBL] [Abstract][Full Text] [Related]
5. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis.
Siamopoulos KC; Elisaf MS; Bairaktari HT; Pappas MB; Sferopoulos GD; Nikolakakis NG
Perit Dial Int; 1995; 15(8):342-7. PubMed ID: 8785232
[TBL] [Abstract][Full Text] [Related]
6. Lipid abnormalities in black renal patients.
Burrell DE; Antignani A; Goldwasser P; Mittman N; Fein PA; Slater PA; Gan A; Avram MM
N Y State J Med; 1991 May; 91(5):192-6. PubMed ID: 1857570
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis.
Avram MM; Fein PA; Antignani A; Mittman N; Mushnick RA; Lustig AR; Lapuz MH; Goldwasser P
Am J Med; 1989 Nov; 87(5N):55N-60N. PubMed ID: 2486549
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk factors in diabetic patients undergoing continuous ambulatory peritoneal dialysis.
Babazono T; Miyamae M; Tomonaga O; Omori Y
Adv Perit Dial; 1996; 12():120-5. PubMed ID: 8865885
[TBL] [Abstract][Full Text] [Related]
9. Variability of peritoneal clearances for apolipoprotein and its relationship to susceptibility for atherosclerotic changes in CAPD.
Fein PA; Fletcher D; Antignani A; Goldwasser P; Jorden A; Lustig A; Avram MM
Adv Perit Dial; 1989; 5():185-90. PubMed ID: 2577408
[TBL] [Abstract][Full Text] [Related]
10. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.
Heimbürger O; Stenvinkel P; Berglund L; Tranoeus A; Lindholm B
Nephron; 1996; 72(2):135-44. PubMed ID: 8684516
[TBL] [Abstract][Full Text] [Related]
11. Concentration of Lp(a) and other apolipoproteins in predialysis, hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients.
Kimak E; Solski J; Janicka L; Ksaziek A; Janicki K
Clin Chem Lab Med; 2000 May; 38(5):421-5. PubMed ID: 10952225
[TBL] [Abstract][Full Text] [Related]
12. Is atherosclerosis accelerated by CAPD?
Kawaguchi Y; Kubo H; Yamamoto H; Nakayama M; Yokoyama K; Shigematsu T; Sakai O
Perit Dial Int; 1996; 16 Suppl 1():S223-30. PubMed ID: 8728197
[TBL] [Abstract][Full Text] [Related]
13. Adipose tissue fatty acid composition, serum lipids, and serum alpha-tocopherol in continuous ambulatory peritoneal dialysis patients living on the island of Crete.
Nikolakakis N; Kounali D; Tornaritis M; Anastassou A; Papadakis E; Kassotakis G; Kafatos A
Perit Dial Int; 1999; 19(2):154-9. PubMed ID: 10357187
[TBL] [Abstract][Full Text] [Related]
14. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
Tomura S; Nakamura Y; Doi M; Ando R; Ida T; Chida Y; Ootsuka S; Shinoda T; Yanagi H; Tsuchiya S; Marumo F
Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.
Saltissi D; Morgan C; Rigby RJ; Westhuyzen J
Am J Kidney Dis; 2002 Feb; 39(2):283-90. PubMed ID: 11840368
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
[TBL] [Abstract][Full Text] [Related]
17. Lipids in diabetic and nondiabetic hemodialysis and CAPD patients.
Avram MM; Antignani A; Goldwasser P; Lustig A; Fein PA; Mushnick R; Quinones E; Rao Y; Mittman N
ASAIO Trans; 1988; 34(3):314-6. PubMed ID: 3196527
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients.
Fytili CI; Progia EG; Panagoutsos SA; Thodis ED; Passadakis PS; Sombolos KI; Vargemezis VA
Ren Fail; 2002 Sep; 24(5):623-30. PubMed ID: 12380908
[TBL] [Abstract][Full Text] [Related]
19. [Lipoprotein (a) in children with end stage renal failure on maintenance hemodialysis and continuous ambulatory peritoneal dialysis].
Zwolińska D; Szprynger K
Przegl Lek; 1997; 54(5):320-3. PubMed ID: 9380806
[TBL] [Abstract][Full Text] [Related]
20. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
